Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyDisease description

Definition and etiology

12 evidence topics · 7 sources

Definition of BCG-unresponsive disease: FDA guidance

“For the purposes of this guidance, BCG-unresponsive disease is defined as being at least one of” (opens the source at this quote in a new tab)

“Persistent or recurrent Carcinoma in Situ (CIS) alone or with recurrent” (opens the source at this quote in a new tab)

“(noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease” (opens the source at this quote in a new tab)

“within 12 months of completion of adequate BCG therapy” (opens the source at this quote in a new tab)

“disease within 6 months of completion of adequate BCG” (opens the source at this quote in a new tab)

“T1 high-grade disease at the first evaluation following an induction BCG” (opens the source at this quote in a new tab)

“At least five of six doses of an initial induction course plus at least two of three doses of” (opens the source at this quote in a new tab)

“At least five of six doses of an initial induction course plus at least two of six doses of a” (opens the source at this quote in a new tab)

“Patients with BCG-unresponsive NMIBC are unlikely to benefit from further therapy with BCG” (opens the source at this quote in a new tab)

“Patients with BCG-unresponsive NMIBC include those who experienced recurrence with either” (opens the source at this quote in a new tab)

“papillary disease or CIS or both and who have completely resected disease, resected disease with” (opens the source at this quote in a new tab)

“CIS, or CIS alone at trial entry.” (opens the source at this quote in a new tab)

Categories of BCG failure: EAU definitions

“Several categories of BCG failures, broadly defined as any HG disease occurring during or after BCG therapy, have been proposed (see Table 7.2).” (opens the source at this quote in a new tab)

“To be able to specify the subgroup of patients where additional BCG is unlikely to provide benefit, the category of BCG-unresponsive tumour was defined. Further BCG instillations in these patients are associated with an increased risk of progression” (opens the source at this quote in a new tab)

“The category of BCG-unresponsive tumours comprises BCG-refractory and early BCG-relapsing tumours (see Table 7.2)” (opens the source at this quote in a new tab)

“BCG-unresponsive tumours include all BCG refractory tumours and those who develop T1/Ta HG recurrence within six months of completion of adequate BCG exposure” (opens the source at this quote in a new tab)

“or develop CIS within 12 months of completion of adequate BCG exposure” (opens the source at this quote in a new tab)

“Adequate BCG is defined as the completion of at least five of six doses of an initial induction course plus at least two out of six doses of a second induction course or two out of three doses of maintenance therapy.” (opens the source at this quote in a new tab)

“Non-HG recurrence after BCG is not considered as BCG failure.” (opens the source at this quote in a new tab)